Clinical Research Directory

Inclusion Criteria: 1. Abilities to understand and the willingness to provide written informed consent. Assent will be obtained when appropriate based on the subjects age; 2. Patients are ≥ 6 months and ≤ 80 years old; 3. DIPG or GBM patients with existing or measurable tumors in the brain. Patients have received standard care of medication, such as gross total resection with concurrent radio chemotherapy (\~54 - 60 Gy, TMZ); 4. Patients with adequate neurological function and epileptic symptoms that are well controlled; 5. Observing the condition after surgery or without surgery; 6. Karnofsky performance score (KPS) ≥ 60;Life expectancy \>3 months; 7. Important organ function is satisfied: Cardiac ultrasound indicates a cardiac ejection fraction ≥50%; and there is no obvious abnormality in the electrocardiogram; blood oxygen saturation ≥90%; creatinine \<2.5 times normal range; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 3 times normal range; Total bilirubin ≤ 2.0 mg / dl; Hgb (hemoglobin) ≥ 80g / L; 8. Peripheral blood absolute lymphocyte count must be above 0.8×10\^9/L; 9. Adequate Neurologic Function Defined as: Patients with seizure disorder may be enrolled if seizure disorder is well controlled; 10. Patients must be willing to follow the orders of doctors. Exclusion Criteria: 1. A prior history of gliadel implantation 4 weeks before this study start or antibody based therapies; 2. The patient was still using dexamethasone at a dose greater than 4 mg/day during mononuclear cell collection; 3. Patients have a history of autoimmune diseases or other diseases requiring long-term use of hormones or immunosuppressive drugs; 4. Patients with a history of allergies or allergies to immune cells and adjuvants of cellular products; 5. Active infection with fever; 6. Patients with neutropenia (\> 10 days) that are difficult to correct after treatment; 7. Infection with bacteria, fungi or viruses, uncontrolled; 8. Patients with HIV and those living with active HBV and HCV; 9. Pregnant, pregnant and lactating women; 10. Important organ failure (heart, liver, kidney, lung); 11. Patients who had previously been treated with cell therapy but were ineffective after physical examination were discussed and confirmed by team experts and were not suitable for re-treatment; 12. Anything that researchers believe may increase the risk of subjects or interfere with test results.